| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1030822542 |
| P356 | DOI | 10.1023/A:1011035115342 |
| P698 | PubMed publication ID | 11403225 |
| P2093 | author name string | S Rantapää-Dahlqvist | |
| K G Sundqvist | |||
| A Uddhammar | |||
| K Eneslätt | |||
| P2860 | cites work | Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus | Q72332814 |
| Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases | Q73414201 | ||
| Cardiopulmonary bypass-induced inflammation: is it important? | Q74534668 | ||
| Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes | Q77787605 | ||
| Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule | Q24305174 | ||
| Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing | Q24306732 | ||
| Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction | Q25938986 | ||
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
| Matrix metalloproteinases: a review | Q29620220 | ||
| Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis | Q30080034 | ||
| Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity | Q33488225 | ||
| Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity | Q33497763 | ||
| Apoptosis signaling in lymphocytes. | Q33664747 | ||
| Monocyte CD14: a multifunctional receptor engaged in apoptosis from both sides. | Q33669300 | ||
| The apoptosis-1/Fas protein in human systemic lupus erythematosus | Q34131476 | ||
| The lpr and gld genes in systemic autoimmunity: life and death in the Fas lane | Q35161112 | ||
| Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase | Q35785971 | ||
| Metalloproteinase-mediated release of human Fas ligand | Q36365559 | ||
| Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus | Q36376850 | ||
| Fas and Fas ligand: a death factor and its receptor. | Q40398073 | ||
| Fas and Fas ligand: lpr and gld mutations | Q40398275 | ||
| Expression of the functional soluble form of human fas ligand in activated lymphocytes. | Q40806057 | ||
| Fas and FasL in the homeostatic regulation of immune responses | Q40957267 | ||
| The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus | Q40974327 | ||
| Downregulation of Fas ligand by shedding | Q41071790 | ||
| Fas ligand expression and function in systemic lupus erythematosus | Q41085091 | ||
| Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. | Q41094242 | ||
| Fas involvement in cytotoxicity mediated by human NK cells | Q41267782 | ||
| Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases | Q41321495 | ||
| Expression of the Fas ligand in cells of T cell lineage. | Q41350187 | ||
| Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. | Q41525198 | ||
| Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages | Q42112392 | ||
| Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing | Q42951871 | ||
| Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. | Q44441787 | ||
| CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+T cells | Q45971909 | ||
| Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. | Q46863693 | ||
| Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16). | Q47733515 | ||
| Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis. | Q54040290 | ||
| Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome | Q55670225 | ||
| Processing of tumour necrosis factor-α precursor by metalloproteinases | Q59059630 | ||
| A role for CD95 ligand in preventing graft rejection | Q59066471 | ||
| The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis | Q59276652 | ||
| Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege | Q63408406 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 183-192 | |
| P577 | publication date | 2001-05-01 | |
| P1433 | published in | Journal of Clinical Immunology | Q6294961 |
| P1476 | title | The regulation of FasL expression--a distinquishing feature between monocytes and T lymphocytes/NK cells with possible implications for SLE | |
| P478 | volume | 21 |
| Q82249664 | Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus |
| Q82669980 | Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus: relation to the organ damage and lymphocytes apoptosis |
| Q36673286 | Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. |
| Q31143990 | The -844C/T polymorphism in the Fas ligand promoter associates with Taiwanese SLE. |
Search more.